Ignite Creation Date:
2025-12-25 @ 12:33 AM
Ignite Modification Date:
2026-01-01 @ 7:37 AM
Study NCT ID:
NCT05904067
Status:
UNKNOWN
Last Update Posted:
2023-06-15
First Post:
2023-06-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Evaluate the Safety and Efficacy of COVID-19 Convalescent Plasma (CCP) Transfusion to Prevent COVID-19 in Adult Recipients Following Hematopoietic Stem Cell Transplantation
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000086382', 'term': 'COVID-19'}], 'ancestors': [{'id': 'D011024', 'term': 'Pneumonia, Viral'}, {'id': 'D011014', 'term': 'Pneumonia'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018352', 'term': 'Coronavirus Infections'}, {'id': 'D003333', 'term': 'Coronaviridae Infections'}, {'id': 'D030341', 'term': 'Nidovirales Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000093522', 'term': 'COVID-19 Serotherapy'}], 'ancestors': [{'id': 'D019264', 'term': 'Adoptive Transfer'}, {'id': 'D007116', 'term': 'Immunization, Passive'}, {'id': 'D007114', 'term': 'Immunization'}, {'id': 'D007167', 'term': 'Immunotherapy'}, {'id': 'D056747', 'term': 'Immunomodulation'}, {'id': 'D001691', 'term': 'Biological Therapy'}, {'id': 'D013812', 'term': 'Therapeutics'}, {'id': 'D007158', 'term': 'Immunologic Techniques'}, {'id': 'D008919', 'term': 'Investigative Techniques'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 72}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2023-06-10', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-06', 'completionDateStruct': {'date': '2025-01-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2023-06-13', 'studyFirstSubmitDate': '2023-06-13', 'studyFirstSubmitQcDate': '2023-06-13', 'lastUpdatePostDateStruct': {'date': '2023-06-15', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2023-06-15', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-01-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'To evaluate the prevalence of new COVID infection', 'timeFrame': '1 year', 'description': 'within +28 days after the last infusion of CCP'}], 'secondaryOutcomes': [{'measure': 'To evaluate the incidence of severe COVID-19', 'timeFrame': '1 year', 'description': 'within +28 days after the last infusion of CCP'}, {'measure': 'To evaluate the survival rate of COVID-19 infection', 'timeFrame': '1 year', 'description': 'within 30 days after COVID-19 infection within +28 days after last CCP infusion'}, {'measure': 'To evaluate the overall survival', 'timeFrame': '1 year', 'description': 'at 1 year after transplantation.'}, {'measure': 'To evaluate the tolerance of CCP infusion', 'timeFrame': '1 year', 'description': 'at 1 year after transplantation.'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['COVID-19 Convalescent Plasma', 'Hematopoietic Stem Cell Transplantation'], 'conditions': ['COVID-19', 'Hematopoietic Stem Cell Transplantation']}, 'referencesModule': {'references': [{'pmid': '41394817', 'type': 'DERIVED', 'citation': 'Cao Y, Li Q, Guo W, Xu M, Fang K, Wang F, Zhang R, Li L, Wei J, Liu Z, Liang C, Zhai W, Ma Q, Chen X, Cao W, Yang D, He Y, Pang A, Feng S, Han M, Sun J, Jiang E. Convalescent plasma therapy for COVID-19 prophylaxis in adults early post-hematopoietic stem cell transplantation: one-year outcomes from a randomized controlled trial. Front Immunol. 2025 Nov 28;16:1626775. doi: 10.3389/fimmu.2025.1626775. eCollection 2025.'}]}, 'descriptionModule': {'briefSummary': 'The study is to evaluate the safety and efficacy of COVID-19 convalescent plasma (CCP) transfusion to prevent COVID-19 in adult recipients following hematopoietic stem cell transplantation.\n\n72 patients will be randomized in a 1:1 ratio to receive either CCR (36 patients) or not (36 patients). Patients in the CCP group will receive 200 ml of CCP at +14 days, +28 days, +2 months, and +3 months following hematopoietic stem cell transplantation. Patients in the control group would be routinely given oral ursodeoxycholic acid for +14 days after transplantation.\n\nThe primary goal of the study is to evaluate the safety of CCP and the incidence of COVID-19 infection within +28 days after the last infusion of CCP.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '16 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. receive hematopoietic stem cell transplantation\n2. Be ≥ 16 years of age on the day of enrollment.\n3. Understand the study procedures, alternative treatment available, and risks involved with the study, and voluntarily agree to participate by giving written informed consent.\n\nExclusion Criteria:\n\n1. Positive serological response to known HIV or active hepatitis C virus.\n2. Patients with mental illness or other conditions that do not meet the requirements of research treatment and monitoring.\n3. Unable or unwilling to sign consent form.\n4. Patients with other special conditions assessed as unqualified by the researchers.\n5. Patients suffered COVID-19 infection between day 0 and infusion of CCP after transplantation.\n\nDrop-out and Withdrawal Criteria\n\n1. Failure of engraftment within 30 days of transplantation;\n2. Patients who are not compliant with the requirements of the study and fail to follow the study plan.\n3. Patients receiving prophylaxis for COVID-19 infection by methods other than this protocol during the trial.\n4. A patient may withdraw from the study if he/she does not wish to continue participating in the study, and the date and reason for withdrawal shall be recorded. The investigator may also decide to discontinue a patient from the clinical study if there is an unacceptable risk.'}, 'identificationModule': {'nctId': 'NCT05904067', 'briefTitle': 'A Study to Evaluate the Safety and Efficacy of COVID-19 Convalescent Plasma (CCP) Transfusion to Prevent COVID-19 in Adult Recipients Following Hematopoietic Stem Cell Transplantation', 'organization': {'class': 'OTHER', 'fullName': 'Institute of Hematology & Blood Diseases Hospital, China'}, 'officialTitle': 'Institute of Hematology & Blood Diseases Hospital', 'orgStudyIdInfo': {'id': 'CCP-COVID-19-HSCT-2023'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Recipient of COVID-19 Convalescent Plasma (CCP) Transfusion', 'description': 'Transfusion of COVID-19 convalescent plasma to participants The experimental group (CCP group): 200 ml of CCP at +14 days, +28 days, +2 months, and +3 months following hematopoietic stem cells transplantation.', 'interventionNames': ['Biological: COVID Convalescent Plasma']}, {'type': 'NO_INTERVENTION', 'label': 'Recipient without COVID-19 Convalescent Plasma (CCP) Transfusion', 'description': 'Control group (supportive therapy): patients were routinely given oral ursodeoxycholic acid for +14 days after transplantation.'}], 'interventions': [{'name': 'COVID Convalescent Plasma', 'type': 'BIOLOGICAL', 'otherNames': ['CCP, COVID-19 Convalescent Plasma'], 'description': '200 ml of COVID Convalescent Plasma at +14 days, +28 days, +2 months, and +3 months following hematopoietic stem cells transplantation.', 'armGroupLabels': ['Recipient of COVID-19 Convalescent Plasma (CCP) Transfusion']}]}, 'contactsLocationsModule': {'locations': [{'zip': '300020', 'city': 'Tianjin', 'state': 'None Selected', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Erlie C Plasma', 'role': 'CONTACT', 'email': 'doctor_eljiang@163.com', 'phone': '223909274'}], 'facility': 'Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Institute of Hematology & Blood Diseases Hospital, China', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}